Holen Sie sich die Stockscreener-App
7.99
0.12%
-0.010
Handel nachbörslich:
8.15
0.16
+2.00%
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Why Relay Therapeutics Inc. stock could outperform in 2025July 2025 Short Interest & Long Hold Capital Preservation Plans - ulpravda.ru
Will Relay Therapeutics Inc. stock deliver shareholder valueTrade Entry Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Is Relay Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Chart Pattern Signals - ulpravda.ru
Will Relay Therapeutics Inc. stock benefit from sector rotationQuarterly Risk Review & Low Risk Profit Maximizing Plans - ulpravda.ru
Will Relay Therapeutics Inc. stock split attract more investors2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
How strong is Relay Therapeutics Inc. stock balance sheetWeekly Volume Report & Daily Oversold Bounce Ideas - ulpravda.ru
Why Relay Therapeutics Inc. stock could benefit from AI revolutionWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
How Relay Therapeutics Inc. stock performs in rate cut cyclesRisk Management & Low Drawdown Trading Techniques - ulpravda.ru
CEO Change: Will Relay Therapeutics Inc. stock pay special dividendsEarnings Recap Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Is Relay Therapeutics Inc. stock a buy before product launchesEnergy Sector Updates & Free Professional Investment Consultations - ulpravda.ru
User | guymondailyherald.comRelay Therapeutics, Inc.Common Stock (Nasdaq:RLAY) Stock Quote - FinancialContent
Relay Therapeutics Q3 2025 Earnings Preview - MSN
What makes Relay Therapeutics Inc. stock attractive to growth funds2026 world cup usa national team round of 32 goalkeepers low block defense knockout prediction guide - ulpravda.ru
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking the 72.58% Potential Upside in Precision Medicine - DirectorsTalk Interviews
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - MSN
Aug Action: What makes Relay Therapeutics Inc. stock attractive to growth fundsPortfolio Value Report & Weekly High Conviction Trade Ideas - moha.gov.vn
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Take Profit: Can Relay Therapeutics Inc. stock hit record highs again2025 Valuation Update & Precise Trade Entry Recommendations - moha.gov.vn
Will Relay Therapeutics Inc. stock gain from strong economyFibonacci Retracement Levels & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9%Here's What Happened - MarketBeat
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics signals slowdown to recharge after busy year - Traders Union
Will Relay Therapeutics Inc stock pay special dividendsMarket Sentiment Report & Verified Technical Signals - moha.gov.vn
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY) - simplywall.st
What sentiment indicators say about Relay Therapeutics Inc. stockQuarterly Market Summary & High Win Rate Trade Alerts - Улправда
Can Relay Therapeutics Inc. stock hit analyst price targets2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Is Relay Therapeutics Inc. stock attractive for passive investors2025 Biggest Moves & Risk Managed Investment Entry Signals - Улправда
Can Relay Therapeutics Inc. stock resist market sell offsPortfolio Return Report & Low Risk High Reward Ideas - DonanımHaber
Can Relay Therapeutics Inc. stock hit record highs againTake Profit & High Conviction Buy Zone Picks - DonanımHaber
How Relay Therapeutics Inc. stock reacts to oil pricesTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Alert from Equity-Insider.com was published in error and has been withdrawn - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Australia
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug - Sahm
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com India
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Reports Positive Efficacy Data for Zovegalisib in Metastatic Breast Cancer at SABCS 2025 - Quiver Quantitative
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):